ALD 101

Drug Profile

ALD 101

Alternative Names: ALD-101

Latest Information Update: 13 Apr 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aldagen
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Metabolic disorders
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Metabolic disorders

Most Recent Events

  • 05 May 2014 Discontinued - Phase-III for Metabolic disorders in USA (IV)
  • 08 Feb 2012 Aldagen has been acquired by Cytomedix
  • 08 Dec 2009 Pharmacodynamics data from preclinical studies presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top